KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBITDA (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBITDA for 16 consecutive years, with -$92.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 152.93% to -$92.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $469.0 million, a 14.95% decrease, with the full-year FY2025 number at $469.0 million, down 14.95% from a year prior.
  • EBITDA was -$92.9 million for Q4 2025 at Halozyme Therapeutics, down from $217.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $217.9 million in Q3 2025 to a low of -$92.9 million in Q4 2025.
  • A 5-year average of $95.1 million and a median of $90.7 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 1674.15% in 2021, then crashed 152.93% in 2025.
  • Halozyme Therapeutics' EBITDA stood at $56.5 million in 2021, then skyrocketed by 31.8% to $74.5 million in 2022, then surged by 35.6% to $101.0 million in 2023, then surged by 73.7% to $175.5 million in 2024, then plummeted by 152.93% to -$92.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's EBITDA are -$92.9 million (Q4 2025), $217.9 million (Q3 2025), and $202.4 million (Q2 2025).